The Global Interventional Cardiology Device Market is poised to achieve a remarkable value of $13 billion by 2029. Despite the anticipated decline in prices over the forecast period, primarily driven by market consolidation and bundling, the market is experiencing steady growth and expansion. Developing countries have witnessed an improvement in healthcare accessibility and overall hospital infrastructure, enabling a larger global population to undergo interventional procedures. This expansion has contributed to the market’s progression.
As the market continues to grow and extend its global reach, the competition among the top three contenders, namely Boston Scientific, Abbott, and Medtronic, remains fierce. These companies have exhibited exceptional performance within the market, each with unique factors contributing to their success. In this blog, we delve into the key products and strategies employed by each company, shedding light on the driving forces behind their achievements in the Global Interventional Cardiology Device Market.
Boston Scientific: The Global Interventional Cardiology Device Market Leader
Boston Scientific emerged as the top competitor in the global interventional cardiology device market in 2022. The company secured its leading position across various segments, including coronary stents, balloon catheters, and embolic protection devices. Boston Scientific’s dominance can be attributed to its extensive range of devices and complementary products tailored for interventional cardiology, supported by a robust international sales team.
Boston Scientific’s collaboration with Asahi Intecc proved to be a strategic move to expand its market presence. The partnership led to the development of the COMET™ FFR guidewire product line, which showcased innovative features such as the atraumatic Asahi tip and optimized rail support for seamless device delivery. This collaboration further strengthened Boston Scientific’s portfolio of high-quality and reliable devices, contributing to its dominant position across multiple market segments. The company’s ability to consistently produce trusted and effective devices has played a crucial role in its ongoing success.
Abbott secured the second-leading position in the global interventional cardiology device market in 2022. The company demonstrated its leadership in key market segments including the interventional coronary guidewire market on a global scale. Abbott’s Xience™ DES emerged as the most popular line of coronary stents for chronic total occlusion (CTO) indications, enjoying significant unit sales. With subsequent generations like Xience Alpine®, Abbott continued to enhance its DES offerings.
Furthermore, Abbott expanded its market presence through the acquisition of St. Jude Medical, which added coronary embolic protection devices and many other devices to its portfolio.
Medtronic emerged as the third-leading competitor in the global interventional cardiology device market in 2022, driven by its strong presence in the coronary balloon catheter, interventional coronary catheter, and diagnostic catheter and guidewire markets. Notably, Medtronic excelled in the interventional coronary catheter segment, offering a diverse range of product lines such as Launcher®, Sherpa NX™ Active, Sherpa NX™ Balanced, and Telescope™. These devices combine support, flexibility, and enhanced visualization, making them suitable for various procedure sites.
Medtronic’s extensive range of devices spanning multiple markets enables them to strategically bundle and leverage their position in the competitive landscape, leading to continuous market share growth over time.
Want More Information on the Global Interventional Cardiology Device Market?
Our recently released 2023 Global Interventional Cardiology Device Market Report contains exclusive information on market shares, average selling prices, market trends and MUCH more at a Global Scale. Feel free to request a free sample below!